NephroGenex, a North Carolina-based biotech company specializing in kidney disease, has raised $3.3 million for its $26.8 million Series A funding round. Investors include Care Capital, drug developer BioStratum and
NephroGenex, a North Carolina-based biotech company specializing in kidney disease, has raised $3.3 million for its $26.8 million Series A funding round. Investors include Care Capital, drug developer BioStratum and
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.